简要报告卡铂、每周紫杉醇和 Pembrolizumab 用于 PD-L1 < 50% 的晚期非小细胞肺癌老年患者：真实世界数据。

IF 4.3 3区材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC ACS Applied Electronic Materials Pub Date : 2024-05-18 DOI:10.1016/j.cllc.2024.05.005

{"title":"简要报告卡铂、每周紫杉醇和 Pembrolizumab 用于 PD-L1 < 50% 的晚期非小细胞肺癌老年患者：真实世界数据。","authors":"","doi":"10.1016/j.cllc.2024.05.005","DOIUrl":null,"url":null,"abstract":"<div><div><ul><li><span>•</span><span><div><span>Carboplatin<span>, weekly Paclitaxel (CwP) and </span></span>Pembrolizumab<span> is feasible in patients aged ≥70 with stage IV NSCLC and PD-L1 < 50%</span></div></span></li><li><span>•</span><span><div>Progression-Free Survival and Overall Survival are improved with addition of Pembrolizumab to CwP in this population</div></span></li><li><span>•</span><span><div>Toxicity profile is consistent with that of other populations, although with a higher frequency of anemia</div></span></li><li><span>•</span><span><div>Addition of Pembrolizumab to CwP should be considered in selected patients aged ≥ 70 with stage IV NSCLC and PD-L1 < 50%</div></span></li></ul></div></div>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Brief Report: Carboplatin, Weekly Paclitaxel and Pembrolizumab in Elderly Patients for Advanced Non-Small Cell Lung Cancer With PD-L1 < 50%: Real-World Data.\",\"authors\":\"\",\"doi\":\"10.1016/j.cllc.2024.05.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div><ul><li><span>•</span><span><div><span>Carboplatin<span>, weekly Paclitaxel (CwP) and </span></span>Pembrolizumab<span> is feasible in patients aged ≥70 with stage IV NSCLC and PD-L1 < 50%</span></div></span></li><li><span>•</span><span><div>Progression-Free Survival and Overall Survival are improved with addition of Pembrolizumab to CwP in this population</div></span></li><li><span>•</span><span><div>Toxicity profile is consistent with that of other populations, although with a higher frequency of anemia</div></span></li><li><span>•</span><span><div>Addition of Pembrolizumab to CwP should be considered in selected patients aged ≥ 70 with stage IV NSCLC and PD-L1 < 50%</div></span></li></ul></div></div>\",\"PeriodicalId\":3,\"journal\":{\"name\":\"ACS Applied Electronic Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-05-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Electronic Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1525730424000846\",\"RegionNum\":3,\"RegionCategory\":\"材料科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENGINEERING, ELECTRICAL & ELECTRONIC\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1525730424000846","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}

引用次数: 0

摘要

-卡铂、每周紫杉醇（CwP）和 Pembrolizumab 可用于年龄≥70 岁的 IV 期 NSCLC 患者，且 PD-L1 <；Pembrolizumab在CwP中的应用提高了无进展生存期和总生存期-毒性特征与其他人群一致，但贫血发生率较高-在CwP中添加Pembrolizumab，应考虑用于年龄≥70岁的IV期NSCLC和PD-L1 <50%的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Brief Report: Carboplatin, Weekly Paclitaxel and Pembrolizumab in Elderly Patients for Advanced Non-Small Cell Lung Cancer With PD-L1 < 50%: Real-World Data.

•
Carboplatin, weekly Paclitaxel (CwP) and Pembrolizumab is feasible in patients aged ≥70 with stage IV NSCLC and PD-L1 < 50%
•
Progression-Free Survival and Overall Survival are improved with addition of Pembrolizumab to CwP in this population
•
Toxicity profile is consistent with that of other populations, although with a higher frequency of anemia
•
Addition of Pembrolizumab to CwP should be considered in selected patients aged ≥ 70 with stage IV NSCLC and PD-L1 < 50%

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

ACS Applied Electronic Materials Multiple-

CiteScore

7.20

自引率

4.30%

发文量

567